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Abstract Chronological age (CA) is determined by
time of birth, whereas biological age (BA) is based
on changes on a cellular level and strongly correlates with morbidity, mortality, and longevity. Type
2 diabetes (T2D) associates with increased morbidity
and mortality; thus, we hypothesized that BA would
be increased and calculated it from biomarkers collected at routine clinical visits. Deidentified data was
obtained from three cohorts of patients (20–80 years
old)—T2D, type 1 diabetes (T1D), and prediabetes—and compared to gender- and age-matched nondiabetics. Eight clinical biomarkers that correlated
with CA in people without diabetes were used to calculate BA using the Klemera and Doubal method 1
(KDM1) and multiple linear regression (MLR). The
phenotypic age (PhAge) formula was used with its
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predetermined biomarkers. BA of people with T2D
was, on average, 12.02 years higher than people
without diabetes (p < 0.0001), while BA in T1D was
16.32 years higher (p < 0.0001). Results were corroborated using MLR and PhAge. The biomarkers
with the strongest correlation to increased BA in T2D
using KDM were A1c (R2 = 0.23, p < 0.0001) and systolic blood pressure (R2 = 0.21, p < 0.0001). BMI had
a positive correlation to BA in non-diabetes subjects
but disappeared in those with diabetes. Mortality data
using the ACCORD trial was used to validate our
results and showed a significant correlation between
higher BA and decreased survival. In conclusion, BA
is increased in people with diabetes, irrespective of
pathophysiology, and to a lesser extent in prediabetes.
Keywords Biological age · Chronological age ·
Diabetes
Introduction
The rate of aging varies among species as evidenced
by variation up to 100-fold in lifespan among mammals [1]. Members of the same species also vary in
the rate of aging, which correlates with their susceptibility to disease, impairment, and death [2].
Hence, individuals of identical chronological age
(CA), defined as years lived since birth, can have
significant variations in their biological age (BA),
the age indicative of the body’s rate of cellular
Vol.:(0123456789)
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decline or physiological breakdown. Variations in
the rate of BA have been shown to be a reliable predictor of mortality, performing significantly better
than CA [2].
The concept of BA was first introduced in 1969 as
an effort to understand variables that affect mortality and the aging process [3] and refers to quantifiable
changes on a cellular level analyzed through biomarkers that can determine specific effects and intensities of
disease. According to the National Institutes of Health’s
biomarkers definitions, a biomarker is a characteristic
that is objectively measured and evaluated as an indicator of normal biological, pathogenic, or pharmacological responses [4]. However, given the complex nature
of aging and its associated pathologies, there is not a
single biomarker that can be used to calculate BA accurately. Instead, a battery of biomarkers that correlate
with aging have shown to be useful in calculating BA
[2, 5]. Epigenetic markers and DNA methylation levels
are considered the gold standard to calculate BA [6–8].
However, these methods have proven to be expensive
and time-consuming, impossible to perform routinely
in large populations. Thus, the ability to calculate BA
from routinely collected clinical biomarkers provides a
powerful tool to predict and monitor health span as well
as age-related illnesses such as cardiovascular disease
[9], cancer [10], neurodegenerative diseases [11], and
type 2 diabetes (T2D).
Over 30 million people are diagnosed with T2D in
the USA, most of whom are over 60 years old. Their
risk for mortality is 50% higher, and life expectancy is
approximately 5 years shorter among men and 7 years
shorter among women who have T2D compared to
those who do not [12, 13]. Additionally, T2D correlates
with significant morbidity and increased risk of serious
health complications which further impair health span
and lifespan in this population such as blindness, kidney
failure, heart disease, stroke, and amputations.
Understanding the correlation between diabetes
and BA is important. The current pandemic caused by
SARS-CoV-2 further emphasizes the added burden that
patients with both type 1 diabetes (T1D) and T2D face.
In this unique situation, COVID-19 severity is tripled
in the diabetes community [14] where advanced age is
one of the main risk factors for complications and death
further suggesting a correlation between BA and T2D.
Given the increased morbidity and mortality associated with T2D in a variety of settings, we hypothesized that BA would be increased in individuals with
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a T2D diagnosis and this would be reflected using
mathematical models that employ clinically available
biomarkers. We used six different cohorts: patients
with T1D and T2D from Joslin Diabetes Center,
cases with diabetes, prediabetes, or without a diabetes diagnosis from the National Health and Nutrition Examination Survey 2017–2018 (NHANES),
and T2D cases who were recruited in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD)
Trial. BA was calculated using the Klemera and Doubal method 1 (KDM1) due to its high predictive value
[2] and phenotypic age (PhAge), due to its strong correlation with morbidity and mortality [15]. Results
were corroborated using multiple linear regression
(MLR) and validated using long-term mortality data.
Herein, we show that 8 biomarkers significantly
correlated with CA in the control population and
were used to calculate BA in groups with T2D, prediabetes, T1D. Seven biomarkers (due to the absence
of blood urea nitrogen) were used to calculate BA in
the ACCORD trial at the time of recruitment. BA of
individuals with T2D, T1D, and a NHANES diabetes
cohort was significantly increased. The prediabetes
cohort also showed an increase but to a lesser extent.
Additionally, we calculated the age ratio, defined as
BA/CA, as a surrogate marker of the rate of aging
which showed that A1c and systolic blood pressure
had the strongest predictive value of age ratio in T2D.
Furthermore, we found that BA significantly correlated with mortality risk in longitudinal data from the
ACCORD trial validating our results. We conclude
that Diabetes mellitus (both type 1 and type 2) significantly increased BA and correlated with long-term
mortality risk.
Methods
Study population
This study was approved by the Joslin Diabetes
Center’s Committee on Human Studies (CHS) which
determined that it represents human subject research
exempt human subject research under 45 CFR 46.104
(d)(4)(ii): it involves the secondary research use of
previously collected identifiable private information
which was recorded in such a manner that the identity
of the human subjects cannot be ascertained directly
or through identifiers.
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Deidentified clinical data was obtained from
male and female subjects, between the ages of 20
and 80 years of age from five different groups: T2D
(n = 686) and T1D (n = 540) from the Joslin Diabetes
Center Clinic; diabetes (which does not distinguish
between T1 and T2) (n = 284), prediabetes (n = 76),
and people without diabetes (n = 873) from NHANES
2017–2018. The NHANES population is described as
a noninstitutionalized civilian resident population of
the USA [16]. The study includes their socioeconomic
status, ethnicity, private health interview, lab tests, and
routine physical exams. Every diabetes and prediabetes case was matched by age and gender with a person
without diabetes. In the selection of the non-diabetes
group, only cases with A1c levels lower than 5.7% were
included, such that non-diagnosed prediabetes cases
were excluded, as defined by the American Diabetes
Association [17]. Additional exclusion criteria included
(1) missing clinical values and (2) subject without gender and CA information. Other chronic diseases were
not used in the exclusion criteria because in some
cohorts the information was not readily available and
we wanted a representation of subjects with diabetes
that represented comorbidities that are usually present.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial followed 10,251 T2D adults,
ages greater than 40, for 4–8 years with a mean of
5.6 years [18, 19]. Deidentified clinical data was
obtained from participants at baseline and correlated
with mortality in the follow-up data. Those participants with incomplete clinical data for the 7 biomarkers used in the KDM were excluded.

correlations between biomarkers, but no correlation
coefficient exceeded 0.75 in absolute value; therefore,
no biomarkers were removed. Outlying observations
were shrunk through winsorization (i.e., shrinking
outlying observations of biomarkers to the border of
the main part of the data) and adequate biomarkers
were selected using simple univariate linear regression on gender-adjusted data of non-diabetic subjects.
A total of eight biomarkers were selected based on
this criterion (Table 1) to analyze T2D, T1D, and diabetes in the Joslin and NHANES 2017–2018 cohorts:
creatinine (mg/dL), Serum Albumin (g/dL), cholesterol (mg/dL), urea nitrogen (mg/dL), systolic blood
pressure (mmHg), diastolic blood pressure (mmHg),
pulse (per min), and A1c (%). Additional analysis
substituted A1c by C-reactive protein (CRP) since
diabetes inherently affects the former. CRP was used
as it has a strong correlation with BA [2] and is frequently used in other models [20].
Due to the absence of blood urea nitrogen in the
ACCORD Trial, a total of seven biomarkers were
selected based on this criteria (Table 1) to analyze T2D:
creatinine (mg/dL), albumin (g/dL), cholesterol (mg/
dL), systolic blood pressure (mmHg), diastolic blood
pressure (mmHg), heart rate (per min), and A1c (%).
The PhAge model requires that 9 biomarkers are to
be included: glucose (mmol/L), albumin (g/L), creatinine (umol/L), red cell distribution width (%), white
blood cell count (1000 cells/L), alkaline phosphate
(U/L), C-reactive protein (mg/dL), lymphocyte percent
(%), and mean cell volume (fL). Due to the absence of
biomarkers in the ACCORD and Joslin Cohorts, only
the NHANES cohort was used for this analysis.

Selection of biomarkers
The selection of clinical biomarkers to calculate BA
was based in biomarkers obtained from individuals
without a diagnosis of prediabetes or diabetes and
with an A1c < 5.7%. The aim was to find biomarkers that correlated with CA and could be used to calculate BA. For each clinically available biomarker,
we performed Box–Cox transformation to achieve
normal distribution followed by standardization.
Box–Cox transformation could not be applied to diastolic blood pressure in the NHANES cohort because
one individual had a zero value, but it was already
approximately normally distributed. We assessed
whether biomarkers were redundant by examining the

Table 1  Biomarkers that correlated with CA in non-diabetic
individuals. These biomarkers were used to calculate BA in
T1D and T2D from the Joslin Cohort
Biomarker

p value

R2 value

Creatinine (mg/dL)
Systolic blood pressure (mmHg)
Blood urea nitrogen (mg/dL)
Albumin (g/dL)
A1c (%)
Cholesterol (mg/dL)
Pulse/min
Diastolic blood pressure (mmHg)

7.0 × 10–3
1.3 × 10–9
3.9 × 10–3
1.1 × 10–2
2.0 × 10–5
1.2 × 10–10
1.6 × 10–2
6.6 × 10–4

0.36
0.26
0.05
0.06
0.03
0.07
0.03
0.03
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Klemera and Doubal method 1 (KDM1)
BA was calculated using KDM1 [2, 21] (INSERT REF
21) using the selected 8 biomarkers by multiple linear
regression in control males and females separately. Two
thirds of the NHANES non-diabetic control subjects
were used to train the KDM algorithm and independent
subjects were used as controls (Suppl. Tables 1 and 2).
The KDM1 is based on 4 presumptions:
1. Speed of aging is different among species and
individuals;
2. BA = CA + RAB (0; S2AB);
3. Biomarkers used must significantly correlate with
CA;
4. X = FX (BA) + RX (0; S2X). Where RAB (0;
S2AB), RX (0; S2x) are random variables with
zero mean and variance S2AB , S2x respectively,
and Fx(BA) is the governing function of a biomarker by BA Detailed steps of KDM were carried out by computer programming by entering the
data of indicators such that the model was generated. KDM was run using the R package biomed
at https://github.com/bjb40/bioage.

PhAge = 141.50 +
where

ln[−0.0053xln(1 − xb)]
0.09165

xb = −19.907 × 0.0336 × albumin
+0.0095 × creatinine
+0.0195 × glucose
+0.0954 × ln(CRP)
−0.0120 × lymphocytepercent + 0.0268

×meancellvolume + 0.3356 × redbloodcelldistributionwidth
+0.00188 × alkalinephosphatase
+0.0554 × whitebloodcellcount
+0.0804 × chronologicalage

Calculation of dAge and age ratio
Delta age (dAge) was calculated as the difference
between BA and CA (dAge = BA-CA) and reflects the
difference in years between both.
The age ratio between BA and CA was calculated
as age ratio = BA/CA to reflect the rate of aging of
people with diabetes and the selected biomarkers at
a specific moment whether a person appears older
(value > 1) or younger (< 1) than expected based on
their CA. It provides equivalent information as phenotypic age acceleration used in Levine [24, 20].

Multiple linear regression (MLR)

Mortality analysis

We fit biological age parameters using the 8 biomarkers by multiple linear regression in CTRL males and
females separately. We then use training data to calculate out-of-sample biological ages in diabetic (T1D and
T2D) males and females separately.
Using the MLR model, aging biomarkers are
determined based on their correlation with CA [22].
∑m
BAi = b0 +
bj xji

dAge was calculated at baseline using KDM for individuals recruited to the ACCORD trial with seven biomarkers as specified above. Using SAS v.9.4 (SAS Institute,
Cary, NC), we conducted a time-to-event analysis to
examine the effects of dAGE, as a continuous predictor,
on progression to total mortality in all ACCORD participants without missing biomarker data (n = 10,093). Coxproportional hazards regression models were applied for
this analysis, and trial covariates (glycemic, blood pressure, and lipid trial assignments) were included in the
model. For illustration purposes, Kaplan–Meier curves
were plotted to demonstrate the effects of dAGE above
vs. below the median on total mortality in ACCORD.

j=1

Phenotypic Age (PhAge)
Phenotypic age was calculated using [23], in which used
9 biomarkers (albumin, glucose, C-reactive protein, lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline phosphatase, and white blood cell
count). The equation developed by Levine et al. to calculate phenotypic age is as follows:

13

Statistical analysis
Statistical analysis was performed using Mann–Whitney-Wilcoxon Test (Wilcoxon rank sum test) in R and
Prism.
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Results

Diabetes mellitus correlated with increased BA

Clinical biomarkers correlate with chronological age
in a non‑diabetic population
The NHANES 2017–2018 survey was queried for
men and women aged 20–80 without a diabetes diagnosis of diabetes and an A1c < 5.7 to exclude undiagnosed prediabetes [17]. A total of 1798 individuals
were included in the search of clinical biomarkers
that significantly correlated with age. Eight biomarkers (Table 1) were chosen due to the limited availability of biomarkers included in the Joslin T1D and T2D
clinical records, and they significantly correlated with
CA. The statistical significance of their correlation
with CA varied between 1.2 × 10–10 and 1.1 × 10–2.
The R2 value of creatinine exceeded 0.32 and therefore failed to mitigate the effects of the CA paradox
[21]. These biomarkers were chosen to calculate BA
in the T2D and T1D cohorts and NHANES 2017–18
prediabetes and diabetes groups. BA was calculated
in the ACCORD Trial subjects with the same biomarkers, excluding blood urea nitrogen due to its
absence in patient records.
A strong correlation between CA and BA was
observed for people without diabetes (R2 = 0.65,
p < 0.0001) (Fig. 1) validating the selected biomarkers and KDM1 as an adequate mathematical model to
calculate BA in this population. The strong relationship between CA and BA highlights the convenience
of using accessible clinical biomarkers to estimate
BA once adequate validation of their correlation with
CA has been performed.

Using KDM1 and the identified biomarkers, BA was
calculated in people diagnosed with T2D and their
dAge (dAge = BA-CA) compared to CA. On average, dAge of people with T2D in the Joslin cohort
was 12.02 years greater than those without diabetes (p < 0.0001) (Fig. 1). However, the spread of BA
across the population of T2D indicates a variety of
additional factors that influence BA alongside a T2D
diagnosis. There was a considerable proportion of
patients within the diabetes cohort who had a BA
lower than their CA indicating that by no means, a
diagnosis of T2D inevitably lead to accelerated aging.
To understand whether the increased BA preceded
the development of T2D, a population of prediabetes
was queried for BA (Fig. 1). Prediabetes was characterized by a 2.69-year significant increase in BA with
respect to matched individuals, suggesting that the
most significant increase in BA observed in the population with T2D occured after the diagnosis instead
of leading up to it. Therefore, accelerated cellular age
did not seem to be one of the causal factors of T2D
but rather a result of it.
One of the main risk factors to develop T2D is
increased age which might suggest that the correlation between the disease and increased BA might
be an epiphenomenon brought about by increased
CA. We therefore selected a cohort of people with
T1D, whose onset is characteristically during childhood or early adolescence [25], and inquired whether
in this population a similar change in BA would be
observed. A cohort of 540 people with T1D were
included and revealed a 16.61-year average increase
of BA (p < 0.0001) when compared to age-and gender-matched people without diabetes (Fig. 1). Finally,

Fig. 1  Significant increase in BA in diabetes patients calculated using KDM. a Linear correlation between CA and
BA for non-diabetic control subject (n = 1798); b significant
increase in BA in subjects with prediabetes (n = 66); c signifi-

cant increase in BA in people with T2D (n = 686), an average
of 12 years greater than controls; d BA in people with T1D
(n = 540) and e BA in people with diabetes (T1 and T2D)
(n = 284)
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to corroborate these results in a different cohort, BA
in NHANES diabetes reported patients was calculated and a significant increase of BA was confirmed
when compared to a non-diabetes population (Fig. 1).
These results reveal a significant increase in BA
with diabetes mellitus, irrespective of age of diagnosis and of the underlying pathophysiology of the
disease (metabolic for T2D versus autoimmune for
T1D).
Age ratio correlates with modifiable biomarkers
We have defined age ratio as a surrogate marker of the
rate of aging. It determines the correlation between
BA and CA (BA/CA) at a given point in time and provides a quantitative value between both ages. An age
ratio of 1 indicates a perfect match between BA and
CA whereas values > 1 correlate with faster cellular
aging and values < 1 correlate with a slower one compared to chronological aging.
To study the contribution of each of the selected
biomarkers to BA, linear correlation between biomarkers and the age ratio was calculated for the population
with T2D (Fig. 2, Suppl. Figure 1). The two biomarkers with the strongest correlation to age ratio using
KDM were A1c (Fig. 2), and systolic blood pressure
(Fig. 2); which tightly correlate with metabolic control
and cardiovascular health. Other biomarkers that correlate with age ratio using KDM were creatinine and
blood urea nitrogen (Fig. 2) reflective of liver and renal
function, respectively. Cholesterol, diastolic blood
pressure, albumin, and pulse had the weakest correlations to age ratio using KDM (Suppl. Figure 1).

These data underline the importance of proper
metabolic control and blood pressure as effective
measures to potentially counteract the accelerated BA
observed in T2D and is a novel way to interpret and
evaluate therapeutic strategies. Interestingly, the correlation between age ratio and individual biomarkers
in the population of T1D was much weaker than for
T2D, except for A1c, (Suppl. Figure 2). The reason
for this dissociation in T1D is unclear and requires
further studies.
Multiple linear regression (MLR) confirms increased
BA with Diabetes mellitus
Confirmation of BA results was performed using a
complementary mathematical model to estimate its
values in the same three populations—NHANES
diabetics, prediabetes, and T1D—and compared to a
non-diabetes population.
The correlation between CA and BA among
people without diabetes using MLR (Fig. 3A)
(R2 = 0.41, p < 0.0001, slope = 0.19) was not as
strong as when KDM1 was used. This is consistent
to what has been described in other studies [26, 27],
and one of the reasons why KDM1 is preferred to
calculate BA. Using MLR, people with T2D displayed a 3.94-year increase in BA compared with
age- and gender-matched controls (Fig. 3B) while
in prediabetes the average increase was of 5.2 years
(Fig. 3C). In the T1D population, BA increase
was also confirmed with a value of 10.53 years
(Fig. 3D).

Fig. 2  Biomarkers that are strongly correlated to the BA/CA age ratio in a population of T2D. Correlation between age ratio and
biomarkers: a aA1c (%), b systolic blood pressure (mmHg), c creatinine (mg/dL), and d urea nitrogen (n = 686)
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Fig. 3  Linear model confirmation of increased dAge
in diabetes and prediabetes
cohorts. a Linear correlation between CA and BA
for non-diabetic control
subject as calculated with
LMR (n = 1798). b Higher
dAge in Joslin T2D cohort
(n = 686). c–d Significant
increase in prediabetes
(n = 76) and Joslin’s T1D
cohort (n = 540), respectively

When comparing the two mathematical models,
KDM-estimated BA tended to show larger differences
from CA than MLR, which is consistent with previous
findings that MLR estimates of BA regress towards the
mean (e.g., people older according to BA are estimated
too young) [21]. A main difference between these two
methods is that MLR regresses CA on the biomarkers,
whereas KDM1 treats CA as an independent variable
to find the best model that estimates BA. From a mathematical perspective, the slope of the CA/BA correlation calculated with KDM (Fig. 1) is 1 meaning that in
the population without diabetes, a 1-year increase in CA
will be reflected as a 1-year increase in BA. However,
the slope of the CA/BA correlation calculated with MLR
(Fig. 3A) is 0.19 which means that BA calculated with
MLR underestimates BA.

Both PhAge and KDM correlate with increased BA
in diabetics and prediabetics
To understand the importance of biomarkers used
to calculate BA, we calculated BA using the PhAge
algorithm. A strong correlation between CA and BA
was found in non-diabetics using PhAge (R2 = 0.90,
p < 0.0001, slope = 0.998) (Fig. 4). PhAge found that
prediabetic subjects were 0.89 years greater than
those without diabetes (p < 0.0001) (Fig. 4), while
KDM noted an increase of 2.69 years (p < 0.0001).
In the NHANES diabetic cohort, PhAge calculated
a BA 7.57 years greater than those without diabetes (p < 0.0001) (Fig. 4), and KDM calculated
a BA 5.73 years greater than nondiabetic subjects
(p < 0.0001). The three biomarkers with the strongest
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Fig. 4  Significant increase in BA in prediabetics and diabetics calculated using PhAge algorithm. a Linear correlation between CA and BA for non-diabetic control subjects
(n = 1798). b BA in people with prediabetes (n = 514); c BA

in subjects with diabetes (T1D and T2D (n = 749). Correlation
between age ratio and biomarkers: d glucose (mmol/L), e creatinine (umol/L), and f albumin (g/L) (n = 764)

correlation to age ratio using PhAge were glucose
(mmol/L), creatinine (umol/L), and albumin (g/L)
(Fig. 4).
Validation of results using two independent models (MLR and PhAge) provided confidence in the
selection of biomarkers and in using KDM as a valid
model to estimate BA.

positive and strong correlation between BA and CA
persisted (Fig. 5) as did the significant increase of BA
in a population with prediabetes (Fig. 5) and diabetes
(Fig. 5).
Given the strong correlation that systolic blood
pressure (SBP) with BA in people with T2D (Fig. 2),
BA was recalculated excluding this marker. A positive correlation between BA and CA also persisted
(Fig. 5) as did significant increases in populations
with prediabetes (Fig. 5) and diabetes (Fig. 5).

Persistence of effects of diabetes on BA after
alternate selection of biomarkers
Given the confounding effect that using A1c as a
BA biomarker has in prediabetes and diabetes, recalculation of BA using KDM was done by excluding
A1c and substituting it with CRP, a commonly used
biomarker with a high correlation to CA [2, 20]. A
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Effects of BMI and smoking on BA in a population
with and without diabetes
Given the strong effects that confounding factors such as BMI and smoking can have on clinical biomarkers, BA was calculated across the BMI
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Fig. 5  Substitution of A1c for CRP (CRP+/A1c−) and absence
of SBP (SBP−) in BA calculations continue to show increased
BA in prediabetic and diabetic populations. a Linear correlation between CA and BA for non-diabetic control subjects
with KDM calculation substituting A1c by CRP. b Significant
increase in BA in subjects with prediabetes after KDM calculation substituting A1c by CRP. c Significant increase in BA

in subjects with diabetes after KDM calculation substituting
A1c by CRP; d linear correlation between CA and BA for nondiabetic control subjects after KDM calculation without SBP;
e significant increase in BA in subjects with prediabetes after
KDM calculation without SBP; f significant increase in BA in
subjects with diabetes after KDM calculation without SBP

spectrum and in a smoker and non-smoker population in individuals with and without diabetes. An
increase in BMI was associated with increased BA
(Fig. 6) in a population without diabetes. However,
the significance of this correlation disappeared when
diabetes was present (Fig. 6) probably because of
the overriding effects of A1c and SBP as previously
determined.
Unexpectedly, smoking did not influence the two
populations involved (Fig. 6). This is probably secondary to the selection of biomarkers which did not
include any lung capacity measures, such as FEV1,
which have been shown to correlate with BA [2]. This
emphasizes the importance of biomarker selection for
specific populations.

Association of dAge and long‑term mortality data
validates increased BA in diabetes
A limitation of the results presented so far is their
cross-sectional nature which impairs validation of
results. To address this, BA was calculated in 10,093
individuals enrolled in the ACCORD trial at baseline
and correlated with mortality data during the duration
of the study.
Figure 7 shows the effect of dAge above and
below median (9.85 years) in all ACCORD data.
An increased HR of 1.23 (95% CI 1.06–1.42) was
found when comparing individuals with a dAge equal
or greater than 9.85 years with those with a dAge
below that number indicating that greater differences
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Fig. 6  Effects of BMI and smoking status on BA. a Significant increase in BA as BMI increases in subjects without diabetes. b No significant increase in BA as BMI increases in subjects with diabetes. c No significant increase in BA in subjects

without diabetes as pack-years increases. d No significant difference between BA in subjects with diabetes who were smokers or non-smokers

between BA and CA carry a greater risk of death.
Whereas dAge was calculated at time of enrollment,
the difference in mortality becomes apparent after
2 years of follow up and persists thereafter. Interaction analysis showed no change in dAge (p = 0.25)
after treatment of glycemia between the standard and
intensive glycemic arms. Whereas the ACCORD trial
followed patients for 7 years, subsequent analysis
might find differences secondary to therapeutic interventions after longer follow up as suggested by the
legacy effect [28, 29]. The longitudinal nature of this
analysis validates the presented results.

In summary, our results reveal increased BA in
people with diabetes mellitus which in turn suggests
accelerated aging. Readily available clinical biomarkers were used favoring the use of KDM1 as a convenient model for BA calculation. The increase in BA
seen in both T1D and T2D provide a novel insight
into the way tissues behave along a chronological
scale, in settings with altered glucose metabolism
irrespective of pathophysiological mechanisms. This,
along with the strong correlation between A1c and
the age ratio, underlines the importance of glucose
control in determining aging at a cellular level.

Fig. 7  Kaplan-Meier
for the effect of dAGE
above and below median
in ACCORD populations.
Effects of dAGE above the
median (≥9.85) vs. below
the median (<9.85) on incidence of deaths in 10,093
ACCORD participants.
The hazard ratio (HR) and
p-value are obtained from
a cox-proportional hazards
model examining the effects
of dichotomized dAGE
(above vs. below median)
on total mortality, adjusted
for glycemic, blood pressure
and lipid trial assignments
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Discussion
The correlation between T2D and age is complex, and
studying the disease from an aging point of view can
provide novel mechanisms and therapeutic targets. In
this study, using the KDM1 model to calculate BA
in people with T1D and T2D, we correlated for the
first time at an epidemiological level an increased BA
with the diagnosis of T2D and preceded by prediabetes. The increased BA also observed in T1D, which is
not age dependent, suggests that age acceleration is
dependent on altered glucose metabolism rather than
on peripheral insulin resistance or cell autonomous
mechanisms that characterize T2D.
Understanding the increased BA with diabetes
and the subsequent accelerated aging is critical to
further our understanding of the biology of aging
in health and disease. Multiple studies support the
concept of accelerated aging in diabetes: increased
telomere shortening and mitochondrial DNA depletion in patients with T2D [30] and accelerated aging
of human collagen in juvenile diabetes mellitus as
determined experimentally by enzymatic digestion
[31]. Particularly, cellular senescence has also been
reported to be increased in the setting of glucose
metabolism dysregulation. Hyperglycemia accelerates
vascular aging by inducing senescence in endothelial
cells, a process suggested to be mediated by ASK1
[15] and p38MAPK [23]. Fibroblasts from skin
biopsies underwent cellular senescence earlier if the
donor was diagnosed with T1D or had a strong family
history of T2D [23]. We have shown that β-cell aging
and senescence is accelerated in islets from donors
with T2D and higher body mass indices, a potential
indirect marker of insulin resistance [32, 33].
The ability to measure changes in the rate of aging
using readily available clinical biomarkers represents
a powerful tool to track this phenomenon and to evaluate clinical interventions. Since the KDM1 method
does not limit which biomarkers can be included in
the calculation as long as they have a significant relationship with CA, BA research can be done to study
more markers depending on availability. All of the
8 biomarkers we used (albumin, creatinine, systolic
blood pressure, glycated hemoglobin, diastolic blood
pressure, pulse, cholesterol, and blood urea nitrogen)
overlap with previous reports of biological age analysis by KDM as reported by Levine et al. [2]. However,
that list is more extensive and includes additional

biomarkers such as forced expiratory volume, serum
alkaline phosphatase, C-reactive protein, and cytomegalovirus optical density, which we were unable
to include in our biomarkers list, since they were not
available in our data set. It is interesting to note that
our data did show that pulse was associated with CA
in our non-diabetic controls, whereas the Levine M.
E. study did not. Another interesting difference is the
correlation between age and A1c which is lower in
our study. We believe this is explained by our exclusion of individuals with an A1c equal or greater to
5.7%, defined as prediabetes by the American Diabetes Association (ADA).
Further studies of telomere shortening, DNA
methylation, and mitochondrial DNA depletion
in populations with diabetes would further our
understanding of accelerated aging and would contribute to directly measure the level and extent of
damage accumulation in the body in health and
disease. Identification of the proper DNAm profile would be crucial in these studies since correlations between KDM BA and some DNAm clocks
have been shown to be quite low [34], whereas the
use of machine learning analysis of pace of aging
found to have a better correlation with increased
decline of physical function, cognitive function and
subjective signs of aging over a 7-year period [8].
A recent paper [35] demonstrates that age-related
epigenetic changes can be reverted to DNA methylation profiles characteristics of younger ages,
speaking to the concept of BA being a dynamic,
rather than a static, parameter.
Many of the biomarkers that strongly correlate
to BA are known to be altered in T2D and its complications, implying that disease severity is one
of the determinants of BA. For example, evidence
has shown that premature aging in T2D leads to an
increased risk of cardiomyopathy [27] and our study
found a high correlation between age ratio and systolic blood pressure, which promotes myocardial
remodeling and is a risk factor in the development
of cardiomyopathy [28, 29]. To further evaluate the
effect of disease-dependent biomarkers such as A1c,
we performed KDM analysis in prediabetes and diabetes population excluding A1c and including CRP.
The increase in BA persisted suggesting that there are
cell autonomous mechanisms that are altered in diabetes and are not solely dependent on blood glucose
levels and lead to accelerated aging.
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Additionally, given the strong correlation between
biomarkers such as systolic blood pressure and A1c
to BA and the existence of effective clinical interventions that can modify them, the concept of BA
becomes potentially dynamic and modifiable. Other
studies have shown that BA is modifiable such as
the CALERIE intervention where participants randomized to caloric restriction revealed decrease in the
rate of biological aging [36]. However, interaction
analysis showed no change in BA due to therapeutic
intervention in the ACCORD study analyzed in the
current paper. This could be secondary to the legacy
effect showing lasting changes (up to 10 years) due
to changes in blood glucose levels [28, 29]. Since
this ACCORD cohort was followed for an average of
5–7 years, perhaps further follow-up or inclusion of
additional biomarkers might reveal BA changes after
glucose and blood pressure interventions.
Based on these concepts, we propose BA can be
used as an additional clinical outcome to track the
evolution of individual patients, their lifestyle, and
influence of pharmacological interventions, in such
a way that some biological processes of aging may
be slowed as discussed in the geroscience hypothesis
[37].

Second, the Joslin cohorts are not a nationally representative sample. There are several genetic and environmental factors that affect the aging process that are
important to consider. Thus, we found a relationship
between aging and diabetes here, but the model is yet
to be extended to human aging in general.
Third, the NHANES cohort differentiates patients
based on their response to the question asking
whether they have been diagnosed with diabetes or
prediabetes. Therefore, type 1 and type 2 diabetes
cannot be differentiated in this cohort and the data
relies on the subjective response of the participant,
allowing for the possibility of information bias.
In conclusion, the development and study of aging
beyond traditional CA constraints is vital to understand the aging process and how to address conditions
that affect it. Moving forward, integrating our theoretical and cellular understanding of aging with environmental, behavioral, and heritable factors is necessary
to facilitate future development in the field of aging
and diabetes research.

Significance and limitations of the study
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Most patients with T2D are above the fifth decade
of life, suggesting a correlation between cellular
age and diabetes. This paper identified an increase
in biological age (a reflection of aging at a cellular
level) compared to chronological age (defined by
time since birth) in people with diabetes mellitus.
The significance of these findings is (1) aging at a
cellular level is accelerated in diabetes and (2) biological age, which reflects the rate of aging, can be
calculated using readily available clinical biomarkers
and can guide interventions to improve health span
and lifespan.
Although there was a very strong and consistent
relationship between accelerated aging and diabetes, there are limitations in this study that need to be
addressed.
First, the biomarkers used were limited given the
constraints of NHANES, ACCORD, and Joslin Diabetes Center patient data.
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